Celldex Therapeutics | CLDX - Operating Profit

Stock Price
29.26
Daily Change
0.72 2.52%
Monthly
27.11%
Yearly
47.18%
Q1 Forecast
28.62

Celldex Therapeutics reported $-87.15M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Agenus USD 14.4M 19.26M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Celldex Therapeutics USD -87.15M 13.54M Dec/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Northwest Biotherapeutics USD -14.8M 2.66M Sep/2024
Pfizer USD 4.65B 3.99B Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Roche Holding CHF 9.56B 3.8B Dec/2025